Published in Cancer Weekly, May 8th, 2001
High-dose interferon alfa 2b (IFN alpha 2b) is the only established adjuvant therapy of resectable high-risk melanoma, while GMK is one of the best vaccine candidates for the disease.
J.M. Kirkwood and colleagues at the University of Pittsburgh Medical Center, Pennsylvania, proposed that both given together might be more effective than either alone.
Their Phase II study evaluated the combination of GMK and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2001-05-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.